Immunomodulatory drugs and therapeutic vaccine in chronic hepatitis B infection (Q35621705)

9 August 2017

1 reference

title

Immunomodulatory drugs and therapeutic vaccine in chronic hepatitis B infection (English)

1 reference

9 August 2017

1 reference

1 reference

1 reference

7

Stanislas Pol

1 reference

9 August 2017

Pascal Lebray

1

1 reference

9 August 2017

Anaïs Vallet-Pichard

2

1 reference

9 August 2017

Marie-Louise Michel

3

1 reference

9 August 2017

Hélène Fontaine

4

1 reference

9 August 2017

Rodolphe Sobesky

5

1 reference

9 August 2017

Christian Bréchot

6

1 reference

9 August 2017

publication date

1 January 2003

1 reference

9 August 2017

published in

Journal of Hepatology

1 reference

9 August 2017

volume

39 Suppl 1

1 reference

9 August 2017

page(s)

S151-9

1 reference

Hepatitis B virus infection

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Clinical aspects of hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

The treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Hepatitis B virus immunopathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Virus-specific lymphokine production differs quantitatively but not qualitatively in acute and chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Interferon treatment in patients with chronic hepatitis B: A meta-analysis of the published literature

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Long-term remission of chronic hepatitis B after alpha-interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

A preliminary trial of lamivudine for chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Specific vaccine therapy in chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

1 reference

7 January 2021

Transplantation of hepatitis B immune lymphocytes as means for adoptive transfer of immunity to hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Development of antibodies to hepatitis B virus surface antigen in bone marrow transplant recipient following treatment with peripheral blood lymphocytes from immunized donors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Maintenance of immune memory to the hepatitis B envelope protein following adoptive transfer of immunity in bone marrow transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Recovery from chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Clearance of hepatitis B surface antigen after bone marrow transplantation: Role of adoptive immunity transfer

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Influence of CsA treatment on adoptive transfer of immunity after allogeneic kidney transplantation in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

The potential role of bone marrow transplantation in augmenting donor-derived immunity to hepatitis B after rat liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Suppression of human hepatoma in mice through adoptive transfer of immunity to the hepatitis B surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Chronic graft-versus-host disease: clinical manifestation and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Hepatitis B associated liver failure following bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Pilot study of natural human interleukin-2 in patients with chronic hepatitis B. Immunomodulatory and antiviral effects

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Interleukin 2 treatment does not modify hepatitis B or C replication in human immunodeficiency virus-infected patients: results from a randomized control trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Double-blind, randomized controlled trial of interleukin-2 treatment of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Treatment of chronic hepatitis B with interferon alpha-2b and interleukin-2

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Low Thymosin Alpha-1 Concentrations in Patients Chronically Infected with the Hepatitis B Virus*

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

A randomized, controlled study of thymosin-alpha1 therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Combination low-dose lymphoblastoid interferon and thymosin alpha 1 therapy in the treatment of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Changes in cytokine production during therapy with granulocyte-macrophage colony-stimulating factor in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

A preliminary experience with GM-CSF plus interferon in patients with HBV and HCV resistant to interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Pilot study of recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Efficacy of polyadenylic.polyuridylic acid in the treatment of chronic active hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Induction of anti-hepatitis B surface antigen (HBsAg) antibodies in HBsAg producing transgenic mice: a possible way of circumventing "nonresponse" to HBsAg.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Efficacy and limitations of a specific immunotherapy in chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

DNA-mediated immunization in mice induces a potent MHC class I-restricted cytotoxic T lymphocyte response to the hepatitis B envelope protein

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Maternally transferred antibodies from DNA-immunized avians protect offspring against hepadnavirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Successful nucleic acid based immunization of newborn chimpanzees against hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900336-2

7 January 2021

10.1016/S0168-8278(03)00336-2

Identifiers

DOI

1 reference

9 August 2017

1 reference